Supercharged immune cells take on relapsed leukemia

NCT ID NCT03326921

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found on leukemia cells. The main goals are to see if the cells can be made and given safely, and to find the best dose. Only 24 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered donor T cells (HA-1 TCR T cells)
What this could lead to: If successful, this could offer a new treatment option for leukemia that relapses after a stem cell transplant, potentially improving outcomes for patients with few alternatives.
What could go wrong: This is a very early phase 1 trial with only 24 participants, so it is primarily testing safety and dosing. The treatment may not work, and there are risks of serious side effects like graft-versus-host disease or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE BIPHENOTYPIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute lymphoblastic leukemia acute myeloid leukemia acute undifferentiated leukemia adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm childhood acute lymphoblastic leukemia childhood acute myeloid leukemia chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia juvenile myelomonocytic leukemia leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive mixed phenotype acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes Neoplasm, Residual Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE BIPHENOTYPIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE MYELOID LEUKEMIA ACUTE UNDIFFERENTIATED LEUKEMIA BLAST PHASE CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE CHRONIC MYELOID LEUKEMIA CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE CHRONIC MYELOMONOCYTIC LEUKEMIA JUVENILE MYELOMONOCYTIC LEUKEMIA LEUKEMIA MINIMAL RESIDUAL DISEASE MIXED PHENOTYPE ACUTE LEUKEMIA MYELODYSPLASTIC SYNDROME RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT ACUTE UNDIFFERENTIATED LEUKEMIA RECURRENT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA RECURRENT CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA RECURRENT MYELODYSPLASTIC SYNDROME REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA REFRACTORY BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM REFRACTORY CHRONIC MYELOID LEUKEMIA, BCR-ABL1 POSITIVE REFRACTORY MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.